[Myasthenia gravis, pregnancy and delivery: a series of ten cases].
OBJECTIVE
To study the reciprocal interferences between pregnancy and myasthenia gravis (MG) and to describe obstetric and anaesthetic management during labour and the post-partum period.


METHODS
Retrospective, single centre study.


METHODS
The files of 10 patients with MG, who delivered between October 1994 and May 2002, were examined.


RESULTS
No stillbirth occurred and all pregnancies were brought to term. All patients were maintained on their long-term anticholinesterase medications during pregnancy. Seven exacerbations were detected and controlled, five by increasing the anticholinesterase treatment, one by using plasmapheresis and one by using intravenous immunoglobulins. No patient required admission to the intensive care unit during pregnancy. All patients had a pre-anaesthetic visit at/near 33 weeks of gestation. Delivery was induced for six patients. Regional analgesia was performed early in labour (epidural, n = 7; combined spinal-epidural = 2) using low concentrations of local anaesthetic and no complication was detected. Three patients required a caesarean section for an obstetrical indication. Seven patients delivered vaginally using instrumental extraction (n = 5). During the post-partum period, four patients were monitored in the intensive care unit during 48 h and close neurological follow-up disclosed no exacerbation during the first 6 post-partum weeks.


CONCLUSIONS
MG has no significant effect on the course of pregnancy and delivery, but MG exacerbation can occur, especially in the first trimester. Regional analgesia is medically indicated and must be performed early in labour, using low concentration of local anaesthetic to lessen the risk of motor block.
Chabert
L
L
Département d'anesthésie-réanimation, assistance publique-hôpitaux de Paris, hôpital Antoine- Béclère, 157, rue de la Porte-de-Trivaux, BP 405, 92141 Clamart cedex, France.
Benhamou
D
D
D000328:Adult; D000767:Anesthesia, Epidural; D000773:Anesthesia, Obstetrical; D000775:Anesthesia, Spinal; D002585:Cesarean Section; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D036861:Delivery, Obstetric; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007231:Infant, Newborn; D009157:Myasthenia Gravis / Q000145:classification / Q000150:complications* / Q000188:drug therapy; D010956:Plasmapheresis; D049590:Postpartum Period; D011247:Pregnancy; D011248:Pregnancy Complications; D011256:Pregnancy Outcome
D002800:Cholinesterase Inhibitors; D016756:Immunoglobulins, Intravenous